Logo
x

Search

Subscribe Now

Prurigo Nodularis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

  • October 22, 2021
Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

  • December 9, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.